Delcath Systems Inc (DCTH) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Delcath Systems Inc (DCTH) has a cash flow conversion efficiency ratio of 0.008x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($857.00K) by net assets ($112.71 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Delcath Systems Inc liquidity coverage in days to measure how many days the company can operate on defensive assets alone.
Delcath Systems Inc - Cash Flow Conversion Efficiency Trend (1999–2025)
This chart illustrates how Delcath Systems Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Delcath Systems Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Delcath Systems Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Thaicom Public Company Limited
BK:THCOM
|
0.017x |
|
Taiwan Navigation Co Ltd
TW:2617
|
0.046x |
|
Flagship Communities Real Estate Investment Trust
TO:MHC-U
|
0.030x |
|
Dhipaya Group Holdings PCL
BK:TIPH-R
|
N/A |
|
Somalogic Inc
NASDAQ:SLGC
|
-0.043x |
|
Sansec Technology Co. Ltd. A
SHG:688489
|
N/A |
|
BNY Mellon Strategic Municipals Inc
NYSE:LEO
|
0.008x |
|
Pitti Engineering Limited
NSE:PITTIENG
|
0.097x |
Annual Cash Flow Conversion Efficiency for Delcath Systems Inc (1999–2025)
The table below shows the annual cash flow conversion efficiency of Delcath Systems Inc from 1999 to 2025. For the full company profile with market capitalisation and key ratios, see DCTH market cap overview.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $111.22 Million | $22.52 Million | 0.202x | +174.50% |
| 2024-12-31 | $68.75 Million | $-18.68 Million | -0.272x | +86.28% |
| 2023-12-31 | $15.78 Million | $-31.25 Million | -1.981x | -146.51% |
| 2022-12-31 | $-5.86 Million | $-24.95 Million | 4.258x | +325.17% |
| 2021-12-31 | $11.95 Million | $-22.60 Million | -1.891x | -82.59% |
| 2020-12-31 | $22.08 Million | $-22.87 Million | -1.036x | -127.80% |
| 2019-12-31 | $-6.36 Million | $-23.69 Million | 3.726x | +277.88% |
| 2018-12-31 | $-14.94 Million | $-14.73 Million | 0.986x | +104.34% |
| 2017-12-31 | $678.00K | $-15.40 Million | -22.711x | -338.09% |
| 2016-12-31 | $-1.49 Million | $-14.21 Million | 9.539x | +599.66% |
| 2015-12-31 | $8.60 Million | $-16.42 Million | -1.909x | -122.74% |
| 2014-12-31 | $18.14 Million | $-15.55 Million | -0.857x | +24.35% |
| 2013-12-31 | $30.10 Million | $-34.10 Million | -1.133x | +54.67% |
| 2012-12-31 | $20.01 Million | $-50.01 Million | -2.499x | -74.57% |
| 2011-12-31 | $26.10 Million | $-37.37 Million | -1.432x | -72.88% |
| 2010-12-31 | $29.08 Million | $-24.08 Million | -0.828x | -88.06% |
| 2009-12-31 | $23.76 Million | $-10.46 Million | -0.440x | +33.15% |
| 2008-12-31 | $10.21 Million | $-6.72 Million | -0.659x | -94.31% |
| 2007-12-31 | $16.43 Million | $-5.57 Million | -0.339x | +70.19% |
| 2006-12-31 | $8.09 Million | $-9.20 Million | -1.137x | -374.44% |
| 2005-12-31 | $12.60 Million | $-3.02 Million | -0.240x | +44.79% |
| 2004-12-31 | $6.79 Million | $-2.95 Million | -0.434x | +55.57% |
| 2003-12-31 | $2.17 Million | $-2.12 Million | -0.977x | +10.20% |
| 2002-12-31 | $1.64 Million | $-1.78 Million | -1.088x | -55.01% |
| 2001-12-31 | $3.23 Million | $-2.27 Million | -0.702x | -852.96% |
| 2000-12-31 | $4.91 Million | $-361.26K | -0.074x | +96.69% |
| 1999-12-31 | $490.00K | $-1.09 Million | -2.224x | -- |
About Delcath Systems Inc
Delcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. Its clinical development… Read more